Page 11234..1020..»

You are currently browsing the Nano Medicine category

VYST Stock: Explanation Of 44.85% Increase On Friday – Pulse 2.0

§ October 19th, 2020 § Filed under Nano Medicine Comments Off on VYST Stock: Explanation Of 44.85% Increase On Friday – Pulse 2.0

The stock price of Vystar Corporations (OTCQB: VYST) increased from $0.0343 per share to $0.0746, representing a growth of 44.85% on Friday. What caused the stock price bump? One of the biggest factors for the price increase is a company announcement that was made on Friday. Following the announcement was made, the news spread on social media and the Discord communications service. And as a result over 113 million shares of the company were traded on Friday.

On Friday, the company issued a press release saying that RxAir (owned by Vystar) is preparing the Rx3000 UV Light/HEPA Air Purifier for large-scale manufacturing. The first new Rx3000 UV-C Light/HEPA Air Purifier prototypes made in the USA are now being assembled and tested under the direction of Strategic Link which is Vystars manufacturing management partner. And the company said that the RxAir Rx3000 air purifier is an FDA Certified Class II medical device that has been proven to destroy and remove 99.9% of airborne viruses, bacteria, and particulates through extended exposure to high intensity germicidal UV-C light and HEPA filtration.

The Centers for Disease Control had confirmed that COVID-19 can be transmitted through airborne droplets and a group of U.S. scientists strongly warned that aerosols lingering in the air could be a major source of COVID-19 transmission. As a result, Vystar is seeing an uptick in demand for air purifiers. And Rx3000s FDA clearance as a Class II Medical Device allows for its use in hospitals and other healthcare facilities to reduce the risk of airborne disinfection.

The testing in EPA-certified laboratories shows Rx3000 has been proven effective against harmful pathogens including multiple coronaviruses, H1N1, MRSA, pneumonia, strep, TB, measles, influenza, and the common cold and also neutralizes odors, indoor pollutants, and VOCs (volatile organic compounds). And each portable RxAir unit provides four to eight complete air changes per hour (ACH) for a 1500 to 3000 sq. ft. room to minimize risk of infection from airborne diseases for all in the room. RxAir is going to start taking deposits on Rx3000 pre-orders beginning October 18, 2020.

KEY QUOTES:

Thanks to Strategic Links robust supplier and manufacturing partner network and perseverance, we have been able to complete assembly and testing of the Rx3000 units Made in the USA despite the COVID-related supply chains disruptions. Strategic Link had a monumental task of sourcing all suppliers and a U.S.-based ISO 13485-certified manufacturer in the midst of a pandemic. We are excited to take the final steps toward commercial production. Vystar is currently accepting applications for additional distributors to help meet the increasing COVID-related demand.

Strategic Link and its manufacturing partner Scott Electronics have an incredible engineering team that continually seeks to improve design, manufacture and performance of their clients products. We are implementing their numerous recommendations to improve the performance and functionality of our existing products, and reviewing their concepts for future upgrades and accessories. As we learn more about COVID-19 and any other airborne pathogens that may emerge, we look forward to coordinating R&D efforts with them to always offer the best products to meet customers ever-changing needs.

Steven Rotman, President and CEO of Vystar Corp., owner of the RxAir product line

With the Rx3000 from Scott Electronics approved, the next step will be to complete final recertifications and testing before turning on volume production. We have provided substantial non-recurring engineering (NRE) services to ready the supply chain for commercial production and streamline manufacturing for an improved final product. We will coordinate with Vystar to scale capacity as appropriate.

S.K Chan, President of Strategic Link

Scott Electronics and Strategic Link collaborated to help bring a better product to market in a very short period of time under difficult circumstances. Our team takes pride in the thought that we can be a small part of the solution to reduce the spread of infectious diseases.

Ken Morris, Scott Electronics General Manager

Continuous effective air disinfection in addition to following hygiene protocols and surface disinfection is critical because microscopic aerosolized viruses and bacteria expelled when people talk, breath, cough and sneeze will contaminate any disinfected room instantly. Aerosolized viruses can hang in the air like smoke for hours waiting to infect one who inhales them.

The major advantage of Rx3000 is that it continually swirls air past powerful germicidal UV-C lights for a high intensity dose that inactivates or kills more than 99.9% of airborne viruses, bacteria, mold and fungi and it traps those pathogens, plus airborne particulates, to reduce risk of infection and irritation. Rx3000s patented UV light kill chamber makes it safer for users during HEPA filter changes as the viruses and bacteria caught in the filter are inactive or dead and unable to cause infection, versus active or live viruses and bacteria that may become dislodged and inhaled when changing filters in traditional air purifiers.

Dr. Bryan Stone, MD, Internal Medicine and Nephrology, Chief of Medicine Emeritus for Desert Regional Medical Center, and a member of Vystar Corp.s Board of Directors

Disclosure: I wrote this article myself and I do not have any business relationship with any company whose stock I write about. I am not a financial advisor and all articles are my opinion. You should do your own due diligence and consider talking to a financial professional before investing.

Read more:
VYST Stock: Explanation Of 44.85% Increase On Friday - Pulse 2.0

Read the Rest...

How Minnesota is trying to turn in another storybook season during a nightmare year – Saturday Tradition

§ October 19th, 2020 § Filed under Nano Medicine Comments Off on How Minnesota is trying to turn in another storybook season during a nightmare year – Saturday Tradition

MINNEAPOLIS Even in a pandemic, P.J. Fleck finds a way to deploy his gimmicks.

Bubble machines throughout the Minnesota football facility to remind his players to keep their synthetic bubble during COVID-19. Flipping the 2020 mantra new normal and ingraining the new next in his players craniums.

And the reading of Robert Southeys childrens literary classic Goldilocks and the Three Bears to his team during the infancy of a delayed fall camp.

What we do has got to be just right for our football team, Fleck said less than three weeks ahead of his 4th season as the Golden Gophers head coach one unlike any hes faced in 39 years on this earth and, God willing, never will again. It doesnt matter what somebody else is doing; what matters is whats best for our football team, our players, our situation, our youth, our experience, our depth.

The melding of those factors amid attempts to play major college football during a global health crisis means you could pick any number of kids stories to personify 2020. Maurice Sendaks Where the Wild Things Are. Charlottes Web of Big Ten coronavirus protocols.

Folks here just hope it doesnt end up being Good Night Moon.

The season that was, then wasnt, then was again seems in some ways to hang by a thread before it even begins. Test positive for COVID-19, and a player is out for a third of the season. Have a handful of plus signs come up on the conferences rapid tests, and an entire team is sidelined.

From their president to their players, the Gophers werent all that vocal when the B1G decided in early August to cancel fall football. They certainly didnt lead the charge for its eventual reinstatement.

In an NFL city inside a hockey state with a franchise in every major professional sports league, its easy for outsiders to cast Minnesota as relatively apathetic. Fleck and his players, though, would detest that term if you said it to them.

Its definitely a blessing, quarterback Tanner Morgan said. And it helps us to be able to understand like, hey, nothings given; this is a privilege. What were able to do, play collegiate football in the B1G, is a privilege.

What will they do with that privilege coming off the programs best season since the early 20th century?

There is more than one antagonist in this tale.

Technically, Minnesotas schedule begins in historic fashion with the Little Brown Jug battle on Saturday at TCF Bank Stadium. After that, Michigan, Maryland, Illinois, Iowa, Purdue, Wisconsin, Northwestern and Nebraska stand between the Gophers and their first B1G Championship Game berth since the conference moved to divisions in 2011. They havent won a conference title since 1967 but came within a win against border rival Wisconsin of playing for one last season.

Three Friday night games will give this Little Engine That Could program which upended Penn State and Auburn last season plenty of national exposure. You can bet Fleck and Athletic Director Mark Coyle raised their hands when the league announced it would be scheduling Friday contests.

But Game No. 10 or No. 1, depending on semantics began in the spring. The toughest opponent this fall is microscopic, rapidly spread and continues to befuddle the nations top health experts.

Like every other FBS team trying to give it a go this fall, Minnesota is operating under strict rules. It has been since voluntary workouts were allowed during the summer, but the pressure is up to 11 now that the B1G has handed down its statutes.

The Gophers dont release team-specific COVID-19 results, but it became apparent throughout the offseason the team had been affected. Perhaps its best player, Rashod Bateman, opted out after a bout with the virus that has killed more than 210,000 in the U.S. before choosing to return after the B1G reversed course.

It was strictly health, said Bateman, who contracted the virus during voluntary summer workouts. With the new testing and daily testing protocols, I definitely feel safer being around our facility and being around my teammates and just being a football player here at the University of Minnesota.

In a matter of months, head athletic trainer Mike Sypniak and his staff have had to become their best version of infectious disease experts. They and the teams operations group have overseen the administering of regular tests today, theyre provided via the B1G from a medical-device corporation called Quidel. Biodesix and a contractor for that company come in every day to perform those tests.

Dr. Brad Nelson, an orthopedic surgeon for sports medicine and the universitys athletic medical director, has played an instrumental leadership role in keeping Athletes Village as sterile as possible, too.

The Gophers medical and training staff typically doesnt speak to media. But Fleck has been quick to credit them with giving Minnesota so much as a shot at pulling off a football season.

Our trainers have worked day and night, overtime, put a lot of their health at risk to help our student-athletes, Fleck said. They deserve a lot of credit.

These are what a lot of times people didnt sign up for, but everybodys willing to help.

When a player does test positive, hes immediately confined to his home or dorm room for the mandatory 14 days. Food is dropped off, and coaches and players make an effort to stay in touch till the athlete is allowed out of quarantine.

The hope is those situations will remain at a minimum.

According to data from Johns Hopkins University, Minnesotas case load has remained relatively flat since mid-July. About 113,439 people have contracted the virus, and 2,197 have died.

Fleck said the uncertainty means some players on his team may still opt out. No. 3 wideout Demetrius Douglas already has.

The Bank will be empty save for possibly friends and family during home games as fall turns to winter in the Twin Cities.

One thing is clear: fans, coaches, media, families, friends and the players themselves are going to find out just how much these dudes care about football. Try as administrators might, student gatherings arent going to magically dissipate until a vaccine is released. Temptations to break stride will abound.

Get the virus, and you arent just putting yourself at risk. You could jeopardize an entire season.

Hows that for peer accountability?

Theres sacrifices were all gonna have to make to be able to be successful this fall, and we know how severe COVID-19 can be, Morgan said. And, you know, 21 days is a long time. If you test positive, thats three weeks. So each and every player knows whats at stake. And we know we have to treat each each day like you know, we have to be careful.

Over the course of two months, Bateman went from contracting the virus to preparing for the NFL draft to pursuing a waiver from the NCAA to play to seeing his eligibility restored.

It was a tough time, and I made it out, said Bateman, the reigning B1G receiver of the year. Im the happiest Ive been since all this stuff has been going on.

That stuff included the police killing of George Floyd and the riots, looting and unrest that ensued within miles of campus this summer. Its why Bateman will wear No. 0 this season, to prove that there is zero tolerance for racism, and there is zero doubt about what Minnesota football stands for, he says.

Regardless of todays divided political climate, dont doubt the impact being so close to the epicenter of the U.S.s latest social unrest has had on Bateman and his teammates.

On the field, his return completely changes the complexion of the Gophers offense. Bateman is good enough to have an even better season than he did as a sophomore, and at the very least hell open opportunities for No. 2 wideout Chris Autman-Bell, tight end Brevyn Spann-Ford and other skill players.

Rashod Bateman changes a lot of things, Fleck said. Maybe not so much for our offense, but it changes things for opposing defenses. Having him in there is critical. Theyve either got to put more people in the box to stop the run or put another person over him to take him out of the box to stop him in the pass game.

Morgan had FBSs fourth-best passer rating and was one of the countrys most consistent quarterbacks in 2019. Hell drop back behind one of the sports biggest and most experienced offensive lines, depending on what happens with a couple members playing status.

And Mohamed Ibrahim is back and expected to shoulder the lions share of co-offensive coordinators Mike Sanford Jr. and Matt Simons zone running attack. Ibrahim ran for 1,160 yards as a freshman before sharing carries with Rodney Smith and Shannon Brooks, both graduated, last season.

We just happy that we got a schedule and we got something to look forward to, Ibrahim said. But we still have to prepare every day.

Five FBS programs offered starting middle linebacker Mariano Sori-Marin an athletic scholarship: Brown, Colgate, Cornell, Harvard and Minnesota.

Ask anyone around the program and theyll probably tell you the 2019-20 Big Ten Distinguished Scholar is the smartest cat on the team. Not only that Fleck said, I would probably rank him in the top 3 of who loves football the most.

Sori-Marin is one of just 4 returning starters for a defense that finished No. 10 in the FBS last season. Safety Antoine Winfield Jr., cornerback Chris Williamson, defensive end Carter Coughlin and linebacker Kamal Martin were all drafted.

This is where Fleck and defensive coordinator Joe Rossis ability to develop players will be tested. Success in that department is the only way Minnesota will have a chance to keep pace with Wisconsin, Iowa or possibly a surprise contender in the B1G West.

With the Hawkeyes losing players to the NFL and the Badgers breaking in a new quarterback in Graham Mertz while Jack Coan recovers from foot surgery, it looks like a wide-open race similar to last years.

We might be younger, but I think were deeper, Fleck said. You see a potential up to a certain point, because the person in front of yous playing all the time, well, sometimes that players got to be able to move on for you to be able to really kind of take the top off the jar, and for the grasshopper to jump out of the jar and go to places theyve never gone before.

And I can see that with our defense.

The front seven is particularly thin, but the secondarys the opposite with safety Jordan Howden and cornerbacks Coney Durr and Benjamin St-Juste all back. Defensive linemen Esezi Otomewo, Micah Dew-Treadway and Boye Mafe all have the potential for breakout seasons.

Sori-Marin predicts some surprises this fall.

Every single position, theres studs on this defense, he said. I think the fans are going to be really, really excited about a lot of guys on this team.

Were excited to get after it.

Fleck has kept a close eye on the SEC, ACC and Big 12 games that will have been going on for over a month by the time the B1G kicks off.

I think the one thing thats stood out is football in 2020 is going to be really different than what people have seen at times, Fleck said. Its not any less real than its ever been. Its real, and it counts.

Some Power 5 teams including juggernaut Alabama have struggled tackling. Others have had a hard time hanging on to the ball.

What will a COVID-sidetracked season bring? Players with no experience playing key roles? Games getting moved like weve seen in the NFL?

The fallout will go beyond 2020. With players granted an extra year of eligibility by the NCAA, Minnesota will have a roster logjam to deal with for the next several years.

In some ways, just getting a crack at this thing is gravy. Especially considering this team was practicing with no real purpose in mind a little more than a month ago.

Just dont tell Fleck or his bought-in bunch this isnt a fairytale worth exploring.

Its different, Fleck said, but its very real. And I think thats what makes it really exciting.

Originally posted here:
How Minnesota is trying to turn in another storybook season during a nightmare year - Saturday Tradition

Read the Rest...

Healthcare Nanotechnology (Nanomedicine) Market: Analysis and In-depth Study on Healthcare Nanotechnology (Nanomedicine) Market Size Trends, Emerging…

§ October 19th, 2020 § Filed under Nano Medicine Comments Off on Healthcare Nanotechnology (Nanomedicine) Market: Analysis and In-depth Study on Healthcare Nanotechnology (Nanomedicine) Market Size Trends, Emerging…

The Healthcare Nanotechnology (Nanomedicine) market report offers a comprehensive and in-detail assessment of the Healthcare Nanotechnology (Nanomedicine) market and focuses on the key growth contributors of the market to gain a knowledgeable insight on the market. The report contains a detailed account of the history of the Healthcare Nanotechnology (Nanomedicine) market and a thorough and detailed forecast up to the year 2026.

The report takes into account the important factors and aspects that are crucial to the client to post good growth and establish themselves in the Healthcare Nanotechnology (Nanomedicine) market. Aspects such as sales, revenue, market size, mergers, acquisitions, risks, demands, new trends, threats, opportunities, and much more are taken into account to procure a detailed and descriptive research report on the Healthcare Nanotechnology (Nanomedicine) market.

Request Sample Report @ https://beathanreports.com/request-for-sample-report/36794

Description:

This report offers segmented data categorized as per related segments of the Healthcare Nanotechnology (Nanomedicine) market and as the international markets change, the report has documented all the essential aspects that affect the overall growth curve of the market. The reports cover all the segments extensively and offer a detailed explanation of all the factors crucial to growth.

The given report has been assessed to give maximum benefit to our clients and to establish them among the frontrunners in the Healthcare Nanotechnology (Nanomedicine) market. The report has been compiled by using various analyses that have proven to be a game-changer for many in the Healthcare Nanotechnology (Nanomedicine) market. The research sources and tools used by our analysts to assess the report are highly reliable and trustworthy and are approved by industry experts.

The following players are covered in this report:

Amgen

Teva Pharmaceuticals

Abbott

UCB

Roche

Celgene

Sanofi

Merck & Co

Biogen

Stryker

Gilead Sciences

Pfizer

3M Company

Johnson & Johnson

SmitH& Nephew

Leadiant Biosciences

Kyowa Hakko Kirin

Takeda

Ipsen

Endo International

Request Discount About This Report @ https://beathanreports.com/discount-request-on-report/36794

Competitive Analysis:

The report offers effective guidelines and recommendations for players to secure a position of strength and dominance in the Healthcare Nanotechnology (Nanomedicine) market. The report offers extensive coverage of the competition and has a detailed account of the mergers, acquisitions in the Healthcare Nanotechnology (Nanomedicine) market landscape.

The report includes comprehensive data on mergers and acquisitions that will help the clients to get a complete idea of the market competition and also give you extensive knowledge on how to excel ahead and grow in the market.

Breakdown Data by Type

Nanomedicine

Nano Medical Devices

Nano Diagnosis

Other

Healthcare Nanotechnology (Nanomedicine) Breakdown Data by Application

Anticancer

CNS Product

Anti-infective

Other

Based on regional and country-level analysis, the Healthcare Nanotechnology (Nanomedicine) market has been segmented as follows:

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia-Pacific

Latin America

Mexico

Brazil

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of Middle East & Africa

Have Any Query ask to our Expert @ https://beathanreports.com/get-expert-help/36794

Reasons to buy:

Read more from the original source:
Healthcare Nanotechnology (Nanomedicine) Market: Analysis and In-depth Study on Healthcare Nanotechnology (Nanomedicine) Market Size Trends, Emerging...

Read the Rest...

Contrast Media Market Excessive Growth Opportunities and Trends Estimated in Report Forecast, 2020-2026 – re:Jerusalem

§ October 19th, 2020 § Filed under Nano Medicine Comments Off on Contrast Media Market Excessive Growth Opportunities and Trends Estimated in Report Forecast, 2020-2026 – re:Jerusalem

Facts & Factors (FnF),a leading market research company recently published a research report onResearch Report on Contrast Media Market Size & Share 2020 Covering COVID-19 Impact Analysis and Forecast to 2026to its research database. This[190+] PDF pages Contrast Media Marketreport analyzes the comprehensive overview of the market comprising an executive summary that covers core trends evolving in the market.

Contrast Media Market 2020 Overview and Deliverables

The global Contrast Media market research report delivers an in-depth well-organized perspective of the information associated with theContrast Media market. Several key market contenders have to face challenging situations to hold a significant market share in the global Contrast Media market, which includes industries, production plants, firms, and vendors. In order to be at the leading position, the key player has to reach ahead of others in terms of production, sales, quality, better services, and revenue generation.

The global Contrast Media market report represents the markets data in a better-analyzed way by fragmenting the market in several key segments. The global Contrast Media market research report involves a comprehensive study of different factors influencing the market growth. Along with this, novel technological advancements, a complete profile of key market players ruling the global and regional Contrast Media market are also comprised in the report.

Request an Exclusive Free Sample Report of Contrast Media Market:https://www.fnfresearch.com/sample/contrast-media-market-by-type-barium-based-contrast

(The sample of this report is readily available on request).

The FREE PDF Sample Report Includes:

(Note: The sample of this report is updated with COVID-19 impact analysis before delivery)

Some of Following Top Market Players Profile Included in This Report:

Interested to Know the Full List of Companies Covered in This Report? Use this Link:https://www.fnfresearch.com/sample/contrast-media-market-by-type-barium-based-contrast

What Does This Research Report Cover?

The global Contrast Media market sizereport provides detailed information about the Contrast Media market with an appropriate examination of several parameters and trends influencing its development on a global basis. Based on the examination of influencing growth and limiting parameters, the precise data indicating the future growth trend of the market can be obtained, which is thoroughly explained in the Contrast Media market research report. The information regarding the approaching opportunities that can boost the market capitalization is also included in the report. The report also comprises essential information such as annual revenue generation, market value, expenditure, yearly sales, and other important statistical data, regarding the key market contenders which include several organizations, firms, product manufacturers, vendors, and distributors.

The global Contrast Media market research report bifurcates the market into different segments in order to better analyze the Contrast Media market. The global Contrast Media market report delivers precise investigative information about the varying cutthroat dynamics. A predictable growth trend to be followed by the Contrast Media market is also included in the report.

How COVID-19 Pandemic Impact Contrast Media Market Growth?

The raise of COVID-19 has many businesses struggling and confused about what steps to take to minimize the economic impact. A simple look at the stock market will tell you that coronavirus has led to a volatile economy, but there are numerous other factors at play.

The long-term COVID-19 impact on the business industry is largely still unknown; hence,Facts and Factors market researchanalysts have already covered the effects of COVID-19 on the business industry at a large level, as well as and regional level. Through our coverage below, get a better understanding of the business and economic implications coronavirus has on trends like remote working, consumer shopping behavior, advertising spend, and essential industries like food, medical, travel, and transportation.

Request a Link for Free PDF Brochure covering COVID-19 Pandemic Business Impact on Contrast Media Market:https://www.fnfresearch.com/sample/contrast-media-market-by-type-barium-based-contrast

Global Contrast Media Market Regional Analysis and Key Segments

The global analysis of the markets data is a tough task; so, for ease of understanding and better recognition of market trends, the globalContrast Media market sizereport delivers the information at a regional or geographical level. The report also enlightens the possible impact of administrative laws and policies on the market growth are included in the report. Keeping the above-mentioned factors into consideration along with the past and current situation of the market, the team of professional analysts has generated a predictable market trend to be followed by the market for several upcoming years.

Additionally, the report comprises the overall business chain, through which the growth rate and deterioration rate of the specific industry in the market can be analyzed. The total cost spent on manufacturing the product and analysis of its assembling procedure is also described in the report.

Along with this, the global Contrast Media market report also provides the discussion over the market economy regarding the total revenue generation by the market at the global level, along with the manufacturing techniques and cost, demand, and supply of a generated product or offered services, capacity, consumption, and other related information.

Need Customization? Request a Customized Copy of This Report:https://www.fnfresearch.com/customization/contrast-media-market-by-type-barium-based-contrast

(We customize your report according to your research need. Ask our sales team for report customization.)

The Contrast Media report is an inclusive study of the market, which provides sufficient knowledge to the clients for efficient decision-making with the aim of expanding business considerably in the market. With the help of statistical graphs, figures, flow charts, and real examples, the report represents the analytical data in an efficient way, which would be easily understandable for the readers even by going through the report.

Read Detail Research Report for More Information:https://www.fnfresearch.com/contrast-media-market-by-type-barium-based-contrast

What this Contrast Media Market research report offers:

1. Global Contrast Media Market size, share assessments for the regional and country-level segments.

2. Global market Trends, Drivers, Constraints, Growth Opportunities, Threats, Challenges, Investment Opportunities, and recommendations.

3. Contrast Media Market forecasts for 5 years along with historical data of all the mentioned segments, sub-segments, and the regional markets.

4. Competitive landscaping mapping the key trends.

5. Major company profiling with their detailed strategies, financials, and recent developments.

6. Strategic recommendations for new companies and startups.

8. Supply chain trends mapping the latest technological advancements.

9. Strategic recommendations in business segments based on market estimations.

About Us:

Facts & Factorsis a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our clients/customers conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them inappropriate decision-making and guidance for strategies to expand their business.

Contact Us:

Facts & Factors

USA: +1-347-989-3985

Email:sales@fnfresearch.com

Web:https://www.fnfresearch.com

Originally posted here:
Contrast Media Market Excessive Growth Opportunities and Trends Estimated in Report Forecast, 2020-2026 - re:Jerusalem

Read the Rest...

A transgender man may become the first to receive a penis transplant. Doctors say it would be a ‘quantum leap’ – Business Insider India

§ October 17th, 2020 § Filed under Nano Medicine Comments Off on A transgender man may become the first to receive a penis transplant. Doctors say it would be a ‘quantum leap’ – Business Insider India

A team of Massachusetts surgeons is preparing to perform the world's first-ever penis transplant on a transgender man.

During the procedure, surgeons would take the penis of a deceased donor and transfer it onto a transgender patient who was assigned female at birth.

"This would be a quantum leap if you were able to transplant a real penile structure," Dr. Curtis Cetrulo, a plastic and reconstructive surgeon at Massachusetts General Hospital, told MedPage Today.

Advertisement

The world's first successful penis transplant was performed in 2015 by a team of South African doctors from the Stellenbosch University in Cape Town and Tygerberg Hospital. Doctors told CNN they used the same techniques used during the world's first face transplant for the procedure.

"The penis as an organ has relatively smaller sized blood vessels compared to other organs like the liver or the kidney," Dubin told Insider.

"The penis also requires connecting not only arteries and veins to function appropriately but also requires connecting the urethra which you urinate out of as well as small nerves to help penile sensation, erections, and orgasm."

That's on top of the usual risk of infection, as with any transplant. What's more, the patient will need to be on immunosuppressant drugs for the rest their life, to make sure the body doesn't reject the transplant, which carries health risks.

Dubin told Insider he wasn't sure how much demand there would be for trans patients to get a penis transplant in the future. There are other, good options for bottom surgery like phalloplasty and metoidioplasty, both of which use the patient's own anatomy to construct a penis and don't require immunosuppressant drugs.

"Performing the surgery may be possible, but to perform the surgery while successfully achieving all these functional outcomes [orgasm, erection, and urinating] would be remarkable," Dubin told Insider.

A transgender man was not allowed to donate blood unless he identified as 'female' on his paperwork

Read more:
A transgender man may become the first to receive a penis transplant. Doctors say it would be a 'quantum leap' - Business Insider India

Read the Rest...

Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By…

§ October 17th, 2020 § Filed under Nano Medicine Comments Off on Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By…

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Regenerative Medicine Market.

Trusted Business Insights presents an updated and Latest Study on Regenerative Medicine Market. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Regenerative Medicine Market during the forecast period. It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2020 2029 (Includes COVID-19 Business Impact)

We have updated Regenerative Medicine Market with respect to COVID-19 Business Impact. Inquire before buying

This report focuses on the Regenerative Medicine market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Regenerative Medicine market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.

Global Regenerative Medicine Market: Segment Analysis

The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.

Global Regenerative Medicine Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.

Global Regenerative Medicine Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029. List of Companies Profiled

Report Coverage

The potential to directly alter human genes was first recognized nearly more than 50 years ago. Cell and gene therapy, represent overlapping fields of biomedical research with similar therapeutic goals. Regenerative medicine also comprises of therapeutic tissue engineering and biomaterials -engineered substances used in medical applications to supplement or replace a natural body function. The increased number of the clinical trials and the use of the regenerative medicine for the development of the medicine to treat chronic diseases are some of the factors propelling the regenerative medicine market trends.

The report provides qualitative and quantitative insights on the regenerative medicine industry trends and detailed analysis of market size and growth rate for all possible segments in the market. The market is segments include type, application, distribution channel, and geography. On the basis of the type, the market is segmented into cell therapy, gene therapy, tissue engineering and platelet rich plasma. On the basis of the application, the market is segmented into orthopedics, wound care, oncology and others. On the basis of distribution channel, the regenerative medicine market is segmented into hospitals, clinics and others. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.

Along with this, the regenerative medicine market report comprises analysis of the industry dynamics and competitive landscape. Various key insights provided in the report are prevalence and incidence of diabetes by key countries, advancements in insulin delivery devices, recent industry developments such as mergers & acquisitions, pricing analysis, technological advancements, and key industry trends.

SEGMENTATION

By Product

By Application

By Distribution Channel

By Geography

Key Industry Developments

In September 2020, Takeda Pharmaceutical Company Limited announced the expansion of its cell therapy manufacturing capabilities with the opening of a new 24,000 square-foot R&D cell therapy manufacturing facility at its R&D headquarters in Boston, Massachusetts. The facility provides end-to-end research and development capabilities and will accelerate Takedas efforts to develop next-generation cell therapies, initially focused on oncology with the potential to expand into other therapeutic areas.

The R&D cell therapy manufacturing facility will produce cell therapies for clinical evaluation from discovery through pivotal Phase 2b trials. The current Good Manufacturing Practices (cGMP) facility is designed to meet all U.S., E.U., and Japanese regulatory requirements for cell therapy manufacturing to support Takeda clinical trials around the world.

Takedas Cell Therapy Translational Engine (CTTE) connects clinical translational science, product design, development, and manufacturing through each phase of research, development, and commercialization. It provides bioengineering, chemistry, manufacturing, and control (CMC), data management, analytical, and clinical and translational capabilities in a single footprint to overcome many of the manufacturing challenges experienced in cell therapy development.

In 2018, Novartis received EU approval for one-time gene therapy Luxturna, which has been developed to restore vision in people with rare and genetically-associated retinal disease.

In 2018, Novartis received EU approval for its CAR-T cell therapy, Kymriah. In 2017, Integra LifeSciences launched its product, Integra Dermal Regeneration Template Single Layer Thin for dermal repair defects reconstruction in a one-step procedure.

 

Looking for more? Check out our repository for all available reports on Regenerative Medicine Market in related sectors.

Quick Read Table of Contents of this Report @ Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2020 2029 (Includes COVID-19 Business Impact)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

Read more:
Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By...

Read the Rest...

Microscopy with undetected photons in the mid-infrared – Science Advances

§ October 16th, 2020 § Filed under Nano Medicine Comments Off on Microscopy with undetected photons in the mid-infrared – Science Advances

Abstract

Owing to its capacity for unique (bio)-chemical specificity, microscopy with midinfrared (IR) illumination holds tremendous promise for a wide range of biomedical and industrial applications. The primary limitation, however, remains detection, with current mid-IR detection technology often marrying inferior technical capabilities with prohibitive costs. Here, we experimentally show how nonlinear interferometry with entangled light can provide a powerful tool for mid-IR microscopy while only requiring near-IR detection with a silicon-based camera. In this proof-of-principle implementation, we demonstrate widefield imaging over a broad wavelength range covering 3.4 to 4.3 m and demonstrate a spatial resolution of 35 m for images containing 650 resolved elements. Moreover, we demonstrate that our technique is suitable for acquiring microscopic images of biological tissue samples in the mid-IR. These results form a fresh perspective for potential relevance of quantum imaging techniques in the life sciences.

Midinfrared (IR) imaging and microscopy are extensively used in various fields such as biology and medicine (16), environmental sciences (7), and microfluidics (8). Sensing with mid-IR light exploits the distinct rotational and vibrational modes of specific molecules (9). This spectral fingerprint can be used as a contrast mechanism for mid-IR imaging, circumventing the need for labeling. Such noninvasive and label-free imaging techniques are especially important for bioimaging procedures, as they permit the observation of largely unaltered living tissues. The current state-of-the-art mid-IR imaging technique is Fourier transform IR spectroscopic imaging (10). It heavily relies on IR technologies, namely, broadband IR sources and detectors. While the gap in technology and price between IR and visible sources is slowly closing (11), IR detection technology lags substantially behind its visible counterparts (1214), such as complementary metal-oxide semiconductor (CMOS) and charge-coupled device technologies. Furthermore, IR detectors are costly and technically challenging, often requiring cryogenic cooling, and, moreover, are subject to severe export restrictions due to dual-use issues.

To bypass the need for IR detectors, techniques such as coherent Raman anti-Stokes scattering microscopy (15, 16) were developed. Here, the weakness of the Raman effect and intrinsic noise mechanism require high laser intensities and only permit slow point-by-point scanning. Photothermal lens microscopy (17) and photoacoustic microscopy (18) in the mid-IR are two imaging modalities that are capable of imaging fresh biosamples with high spatial resolution. Nevertheless, raster scanning is required, and sample illumination is comparatively invasive. Other approaches use frequency conversion to shift the detection frequency to the visible while still sensing in the IR region for the highly desired information. Up-conversion methods have demonstrated imaging in the near- and mid-IR (1921), but conversion efficiency and the number of converted spatial modes remain a significant challenge, especially as they scale unfavorably with each other.

A markedly different approach uses the interference of an entangled photon pair with widely different wavelengths and requires neither laser sources nor detectors at the imaging wavelength. Photons at the idler wavelength are used for illumination but remain undetected. The initial proof of concept for wide-field imaging was demonstrated (22) at 1550 nm with moderate spatial resolution. There, the approach was based on induced coherence without induced emission (23, 24), but similar effects can be realized in general by nonlinear interferometers (25). It has also seen use, albeit in a single spatial mode regime for other modalities of sensing, such as spectroscopy (26), refractometry (27), and optical coherence tomography (28, 29). In addition, during the preparation of this manuscript, we became aware of related work by Paterova et al. (30).

In this work, we show how highly multimode quantum nonlinear interferometry forms a powerful tool for microscopic imaging in the mid-IR using only a medium powered visible laser and a standard CMOS camera. We also derive explicit formulas for the field of view (FoV) and resolution for wide-field imaging with highly nondegenerate photon pairs, which are verified experimentally and numerically reproduced using a full quantum formalism (see Supplementary Materials). In our implementation, a nonlinear interferometer is formed by double passing a periodically poled potassium titanyl phosphate (ppKTP) crystal in a folded Michelson geometry (25). As the pump passes the crystal twice, it can generate a single pair of signal and idler photons via spontaneous parametric down-conversion (SPDC) in the first and/or second crystal. The signal and idler modes after the first pass of the crystal are aligned, such that when propagating back for the second pass, they perfectly overlap with the signal and idler modes for the second possibility for the biphoton generation. This results in indistinguishability and, thus, interference of single biphotons generated in the first and/or second crystal. The interference (of only one biphoton with itself) can be fully measured by solely looking at the signal photons with a CMOS camera. It reveals the phase and absorption an idler photon would experience after the first pass. No complex or cost-intensive components are required to realize such a setup.

In this work, the nonlinear crystal was engineered for highly nondegenerate signal and idler wavelengths. Using broadband phase matching (31), the idler wavelength can be selected in a large range between 3.4 and 4.3 m at room temperature, while the corresponding signal wavelength is in the 780- to 820-nm range. The strong spatial correlations between the signal and idler modes ensure that any distinguishing information obtained by the idler field between the first and second pass of the crystal will be encoded onto the interference of the near-IR light after the second crystal. This allows the simultaneous retrieval of both spatially resolved phase and amplitude information of a sample put into the idler arm. We characterize the mid-IR imaging properties of this system with an off-the-shelf CMOS camera. Moreover, the ability to manipulate the FoV and, accordingly, the system resolution is demonstrated. Specifically, using a 10 magnification, details down to 35 m are shown to be detected, which we use for acquiring microscopic images of a biological sample.

The experimental setup is detailed in Fig. 1. The initial characterization of the imaging technique was made in an unmagnified configuration, with both the end mirrors of the interferometer placed at the far-field of the crystal. The sample to be imaged is placed on the idler mirror. While the unmagnified configuration has limited spatial resolution, it provides a straightforward means to characterize the imaging capacity of the system. The lateral resolution was ascertained by measuring the spatial response to an edge knife (Fig. 2B), yielding 322 5 m. The estimated number of spatial modes is 800 20. In addition, a U.S. Air Force (USAF) clear path resolution target was illuminated (Fig. 2C). These values are consistent with the theoretical model (see Supplementary Materials) developed using a theoretical framework generalized from that of ghost imaging (32).

(A) A 660-nm continuous-wave laser pumps a highly nondegenerate SPDC process. The signal and idler fields generated on the first pass of the 2-mm ppKTP crystal are split via a dichroic mirror (DM). The sample to be imaged is placed in the Fourier plane of the idler, which coincides with its end mirror. Both the idler and signal fields are reflected back, recombined, and back-propagated into the nonlinear crystal with the coherent pump field. The resulting signal field is imaged on a CMOS camera. (B) Constructive, destructive, and difference interference images of the signal for a cardboard cutout probed by the mid-IR idler. Scale bar, 2 mm.

The images and data of the unmagnified and magnified setups are presented in orange and green, respectively. (A) Measured FoVs of the unmagnified and magnified setups are 9100 82 and 819 9 m, respectively. (B) Edge response functions fitted to the data of the two imaging arrangements. (C) Measured resolutions of the unmagnified and magnified setups are 322 5 and 35 5 m, respectively. The smallest features in a resolution target that can be resolved for each arrangement are presented. The 10-fold magnification, resulting in the scaling of the resolution and FoV, is manifested in a narrower extend along the horizontal direction (accentuated by the green shaded rectangle in the plots). Orange scale bar corresponds to 2 mm, and green scale bar corresponds to 0.1 mm. Unmagnified (magnified) images were acquired with 1-s integration time and 200 (400)mW pump power.

To demonstrate microscopy, a 10-fold magnification was realized via a telescope in the idler arm. Characterization of the magnified setup was performed in a similar manner, with the results summarized in Fig. 2. The obtained number of spatial modes is 655 57. The system resolution of 35 5 m is below the smallest available line pair for our clear path resolution target (Fig. 2C).

The number of measured spatial modes in the unmagnified (magnified) realization is about 88% (72%) of the theoretical value. We attribute this reduction in both optical arrangements to alignment imperfections, namely, in matching the corresponding imaging planes precisely, as well as chromatic aberrations. In addition, the smaller depth of focus in the magnified regime brings higher sensitivity to mismatch of imaging and sample planes, explaining the variation between the obtained number of modes in the unmagnified and magnified arrangements.

Our built-for-purpose SPDC source yields approximately 108 pairs/s within the filter bandwidth per 400 mW of pump light, which are distributed over around 18.000 pixels covering the FoV on the CMOS camera. This results in approximately 5000 photons per pixel per second, far above the intrinsic camera noise, and leads to the shot noise and visibility-limited signal-to-noise ratios (SNRs) of the unmagnified (magnified) realization of around 25 (8) that we observe in our measurements. This corresponds to a resolvable transmission difference of 4% (12%). The difference between the two realizations stems from the reduced visibility of the magnified arrangement, which we attribute to technical imperfections such as additional losses, alignment imperfections, and aberrations.

The highly broadband nature of the down-conversion source combined with the tight energy correlations shared between the signal and idler on the order of 1 MHz (given by the pump laser linewidth) easily facilitates hyperspectral imaging. In our proof-of-concept demonstration, we use a tunable interference filter with 3.5-nm bandwidth immediately before detection. Figure 3 presents transmission images obtained with the sample illumination spanning from 3.4 to 4.3 m with corresponding spectral selection of around 85 nm in the mid-IR. Note that the spectral resolution can be straightforwardly enhanced by narrower filtering and trading off signal strength.

Obtained signal transmission images for varying mid-IR illumination wavelengths. Scale bar, 2 mm. The spectra were recorded at the signal wavelength with a grating spectrometer and converted to the corresponding mid-IR wavelength.

Last, the potential of the presented method for realistic, biological samples was demonstrated using an unstained histology sample of a mouse heart (Fig. 4). The mid-IR images (Fig. 4B) were obtained by axially scanning the interferometer displacement inside the coherence length and extracting the visibility and phase of the interference signal for each pixel. This eliminates any ambiguity between loss and destructive interference (owing to a nonuniform phase front) that may arise in a single-shot measurement. It also permits straightforward reconstruction of the wide-field phase-contrast images (Fig. 4C). In the resulting images of the mouse heart in Fig. 4C, ii the arrows indicate a portion of the endocardium, the innermost layer that lines the heart ventricles. This can be seen as a dark purple region indicating high absorption. This layer separates the ventricle itself and the myocardium, the cardiac muscle that constitutes the bulk portion of the heart tissue. The images are a testament to the high tolerance of the presented imaging method to loss and scattering.

Histology sample of a mouse heart with (A) bright-field microscopy with visible light for illustration of the part of the sample we investigated with our method. (B and C) Mid-IR microscopy of the same sample with undetected photons for absorption (B) and phase (C) imaging. Scale bar, 200 m. Images were reconstructed by averaging 10 images at 1-s integration time for 15 axial positions within the coherence length of the biphoton. Pump power was 400 mW corresponding to a sample illumination power of less than 20 pW.

We have demonstrated the capacity of mid-IR imaging via nonlinear interferometry for real-world imaging tasks, requiring only cost-efficient components. Via careful addition of a magnification step, we demonstrate imaging of feature sizes down to 35 m.

Furthermore, owing to the use of a broadband SPDC, the extension to hyperspectral imaging is uncomplicated. To demonstrate the real-world promise of this method for nondestructive biological sensing, we have imaged a wet biological sample with a low sample illumination of less than 20 pW. Given this, one must contemplate what underlies the (perhaps unexpected) efficacy of the presented technique. First, because of the SPDC process, for every detected signal photon exists a corresponding idler photon, and owing to the intrinsic unity efficiency of the nonlinear interferometer, any image information carried by that idler photon can be transferred perfectly to the signal photon. Thus, in the absence of loss and mode mismatch, one can effectively consider the mid-IR information detection efficiency to be determined by the efficiency and noise properties of the near-IR camera used to image the signal field, with modern silicon technology permitting near shot noiselimited images with only a few 1000 of photons per pixel per second. Moreover, this technique has an interesting intrinsic scaling advantage when compared with up-conversion imaging approaches. Consider increasing the number of available modes by a factor of N2: Both techniques would require factor N increase in the pump laser waist (and thus the crystal to accommodate it). However, to maintain a constant SNR, nonlinear interferometry requires an N2 increase in the pump power, whereas up-conversion imaging would demand an increase of N3.

While the spatial resolution presented here with our basic optical layout is larger than the resolutions anticipated by the state-of-the-art mid-IR systems (1 to 10 m), the extension to increased imaging capacity is straightforward. The number of available spatial modes is currently limited by the size of the pump waist and, thus, the crystal aperture. With an increase in the crystal aperture from 1 to 4 mm, the number of available spatial modes will grow from 750 to 12,000. Naturally, this 16-fold increase comes at the expense of the per pixel illumination. Small improvements, however, such as optimized camera illumination (2.5 pixels per resolved mode from the existing 5) and increased exposure time (from 1 to 4 s) will return us to the current per pixel illumination, while further gains remain accessible via crystal optimization and increased pump power. These improvements, coupled with more sophisticated approaches to magnification, will yield imaging capacities at the state of the art while surpassing its speed by leveraging silicon camera technology. In addition, the latter also ensures that the pixel number of the camera itself is no longer a potential bottleneck, since sensitive megapixel CMOS cameras are widely available.

Crucially for applications in hyperspectral imaging, the use of a purpose-engineered broadband SPDC source (31) allows a broad wavelength range to probe the sample simultaneously. Harnessing the potential for high spectral selectivityfundamentally limited only by the bandwidth of the pump laserwill fully unlock the potential of this technique. For example, with efficient extraction of the spectral information and a larger crystal aperture, a mid-IR hyperspectral microscopy image with a 10-m spatial resolution and 250 spectral modes could be achieved within a few minutes (see the Supplementary Materials).

In conclusion, we have experimentally demonstrated that nonlinear interferometry with entangled photons provides a powerful and cost-effective technique for microscopy in the mid-IR, harnessing the maturity of silicon-based near-IR detection technology to allow mid-IR imaging with exceptionally low-light-level illumination. We have shown how this technique can be readily extended to hyperspectral imaging across nearly 1 m. A practical biological sample was imaged with quantum light, revealing morphological features with high resolution. Our results pave the way for broadband, hyperspectral mid-IR microscopy with fast, wide-field imaging capabilities, enabling far-ranging applications in biomedical imaging.

A 660-nm continuous-wave solid-state laser delivers the pump beam for the experiment. Using a telescopic arrangement and a dichroic mirror (DM), the pump illuminates the ppKTP crystal with a 430-m waist, maximally covering the 1 2mm crystal aperture. The ppKTP crystal is quasi-phase matched for a collinear type 0 process, specifically engineered to produce highly nondegenerate photon pairs. The photon pairs are ultrabroadband due to group velocity matching, with an idler spectrum from 3.38 to 4.29 m. The emerging signal and idler (and pump) fields are subsequently collimated (focused) by an off-axis parabolic mirror (OPM). Using a DM, the idler is then split from the signal and pump and is incident on a sample placed on the end mirror of the interferometer. The end mirrors of the interferometer (and thus the object) are placed in the Fourier plane of the crystal. The use of lenses between the OPM and the idler and signal end mirrors is primarily for obtaining the desired FoV on the sample and for matching the idler and signal interferometric arms, respectively. In our magnified setup, a 10-fold magnification is introduced in the idler arm via a telescopic arrangement. The pump is reflected using a cold mirror at the focal length of the OPM. The reflected idler, signal, and pump fields back-propagate through the same path, back into the crystal, with the pump again generating signal and idler fields. Before detection, the signal field is filtered using a 3.5-nm bandpass filter. The Fourier plane of the resulting signal field is then imaged on a CMOS camera. The interferometer arm lengths are required to be matched to within the coherence length of the detected light. For the spectrally filtered image, this length is typically 100 m. The Michelson-type interferometer geometry strongly simplifies the alignment process.

Nine- to 12-week-old C57BL/6J mice were euthanized by cervical dislocation. For formalin fixation, hearts were removed, rinsed in ice-cold saline, and placed in 4% formalin. After 48 to 72 hours of fixation, the tissue was rinsed with phosphate-buffered saline and, lastly, embedded in paraffin. The paraffin-embedded hearts were cut in transverse sections to a thickness of 2 to 3 m and transferred to a low-e slide. Slides were stored at room temperature.

Acknowledgments: We would like to thank A. Hochrainer, M. Lahiri, A. Zeilinger, G. B. Lemos, and R. Lapkiewicz for the fruitful discussions about the theory and characterization of spatial resolution in imaging with undetected photons. Funding: The work was funded by Deutsche Forschungsgemeinschaft (RA 2842/1-1). Author contributions: S.R. conceived the idea and supervised the project. I.K. and S.R. designed the experiment. I.K. carried out the experiment with assistance from H.M.C. and S.R. I.K. and H.M.C. analyzed the data. I.K., H.M.C., and S.R. developed the theoretical analysis. E.G.A. and H.B. prepared the biological samples and assisted in interpreting the results. All authors contributed to the preparation of the manuscript. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

See the rest here:
Microscopy with undetected photons in the mid-infrared - Science Advances

Read the Rest...

Endorsement sidestep: MLive ‘will keep its opinion to itself’ on Trump v. Biden – Deadline Detroit

§ October 16th, 2020 § Filed under Nano Medicine Comments Off on Endorsement sidestep: MLive ‘will keep its opinion to itself’ on Trump v. Biden – Deadline Detroit

The publisher of eight Michigan daily newspapers tries for a public disservice spot in the Journalism Hall of Shame, which should be a thing.

In an election year unlike any other, MLive Media Group chooses not to choose because "our mission is to spread light, not heat."

"MLive is not endorsing a candidate in the presidential race," it postsThursday morning, because that wouldn't "add anything of substance to our body of work leading up to the presidential election."

John Hiner, content vice-president, tries toexplaindefend the abdication:

If you skipped your family reunion because you didn't want to hear your cousins political views, then do either of you really want to hear what we think?

Poll after poll is showing that voters are entrenched in their support for their parties and candidates; the needle has moved very little from 2016 to now, or from this spring until now, for that matter. ... The margins [are] thin, and the percentage of undecided voters microscopic.

The election is going to be decided by voter turnout, not by changing minds. So MLive will keep its opinion to itself.

Actually, the needle has moved as Trump's support drops in Michigan since 2016. And the margin between presidential candidates in Michigan is not thin in any September or October poll.

An Oct. 8-12 survey by EPIC-MRA for the Detroit Free Press shows Joe Biden ahead 48%-39%. Modeling by the respected FiveThirtyEight site projects that Biden will carry Michigan by 57.7%-41.6%, a rolling forecast updated daily.

MLive's silent sidestep is called out on its Twitter feed, which draws over 160 comments about the post.

"Imagine thinking this was the right move," a reader tweets. Another says neutrality is wrong "in a state where domestic terrorists are being inflamed by the Republican president."

A third critic calls Hiner's post "absurd," adding: "You can objectively evaluate both candidates and make an informed decision. This is a cop-out."

MLive, a division of Advance Publications, has journalists in Grand Rapids, Flint, Kalamazoo, Saginaw, Jackson, Bay City, Muskegon and Ann Arbor (online only).

In Detroit, the Freep doesn't keep its opinion to itself. Anendorsement editorialsays:

Donald Trumps election was a tragedy whose cost Americans have scarcely begun to reckon.... We call on Free Press readers to support the election of a new president who can restore dignity and integrity to an office debased and diminished by its current occupant. ...

Joe Biden's election is the right medicine for this infection, the course correction we need to reassure an anxious world that the American dream of liberty and justice for all endures.

The Detroit News, which punted four years ago by endorsing Libertarian candidate Gary Johnson, hasn't taken a stand yet on Biden v. Trump.

For its part, MLive claims "we own Michigan news" and says: "We strive to be both an observer and advocate for our local communities." Except when it chooses not to take a stand on a turning-point decision by voters.

Read the original post:
Endorsement sidestep: MLive 'will keep its opinion to itself' on Trump v. Biden - Deadline Detroit

Read the Rest...

Nikon shows off the winners of its 47th small world photo contest – Digital Trends

§ October 16th, 2020 § Filed under Nano Medicine Comments Off on Nikon shows off the winners of its 47th small world photo contest – Digital Trends

Back to Menu

Nikon this week announced the results of its 46th Small World Photomicrography contest. Below, you can see the top 20 entries selected by the judges.

The goal of the NikonSmall World competition has been to share microscopic imagery that visually blends art and science for the general public, said Eric Flem, communications manager of Nikon Instruments, adding, As imaging techniques and technologies become more advanced, we are proud to showcase imagery that this blend of research, creativity, imaging technology, and expertise can bring to scientific discovery. This years first-place winner (below) is a stunning example.

Created by Maryland-based Daniel Castranova, with assistance from Bakary Samasa, the winning entry actually comprises 350 individual images stitched together.

As per Nikon: This image is particularly significant because it was taken as part of an imaging effort that helped Castranovas team make a groundbreaking discovery zebrafish have lymphatic vessels inside their skull that were previously thought to occur only in mammals. Their occurrence in fish, a much easier subject to raise, experiment with, and photograph, could expedite and revolutionize research related to treatments for diseases that occur in the human brain, including cancer and Alzheimers.

Read the original here:
Nikon shows off the winners of its 47th small world photo contest - Digital Trends

Read the Rest...

NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From US FDA -…

§ October 16th, 2020 § Filed under Nano Medicine Comments Off on NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From US FDA -…

Oct. 13, 2020 06:00 UTC

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the first patient has been injected in its phase I study evaluating NBTXR3 activated by radiation therapy for patients with pancreatic cancer. The trial is a being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson) as part of an ongoing clinical collaboration.

Two additional trials from the clinical collaboration received safe to proceed notifications from the United States Food and Drug Administration (FDA): (i) a phase I study evaluating NBTXR3 activated by radiation therapy for patients with lung cancer amenable to re-irradiation; and (ii) a phase I study evaluating NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer. All current and future trials in this clinical collaboration are sponsored and executed by MD Anderson.

A Phase I Study Evaluating NBTXR3 Activated by Radiation Therapy in Patients with Pancreatic Cancer

Pancreatic cancer is a rare, deadly disease that accounts for approximately 3% of all cancers and has a 5-year survival rate of 9%1.

This pancreatic cancer trial is an open-label, single-arm, prospective phase I study consisting of two parts: (i) dose-escalation to determine the recommended phase 2 dose (RP2D) of NBTXR3 activated by radiation therapy; and (ii) expansion at RP2D.

The patient population will include adults (age 18 years) with borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) that are radiographically non-metastatic at screening, and that have not previously received radiation therapy or surgery for pancreatic cancer. Up to 24 subjects will be enrolled and the planned enrollment period is 18 months.

The objectives of the study are the determination of dose-limiting toxicity (DLT), the maximum tolerated dose (MTD), and the RP2D.

Two Additional Phase I Studies in Lung and Esophageal Cancer Pending

A phase I trial investigating NBTXR3 activated by radiation therapy for patients with lung cancer amenable to re-irradiation, and a phase I trial investigating NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer have been deemed safe to proceed by FDA. Safe to proceed notifications are delivered once the agency is satisfied with the information contained in an investigational new drug application (IND) or any additional information or clarification has been provided.

Lung cancer is the second most common cancer type, and the leading cause of cancer death for both men and women. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a 5-year survival rate of 24% worldwide.2

The lung cancer trial is an open-label, two-cohort, prospective phase I study consisting of two parts: (i) a radiation therapy safety lead-in, and NBTXR3 activated by radiation therapy dose-finding to determine the RP2D; and (ii) expansion at the RP2D with toxicity monitoring.

The patient population will include adults (age 18 years) with inoperable, locoregional recurrent (LRR) non-small cell lung cancer (NSCLC) stage IA to IIIC that are radiographically non-metastatic at screening and have previously received definitive radiation therapy. Cohort 1 will evaluate the safety of intensity-modulated radiation therapy (IMRT) monotherapy in 10 patients. Up to 24 subjects will be enrolled in cohort 2. Recruitment is expected to begin in 4Q2020 and the planned enrollment period is 36 months.

Esophageal cancer is the eighth most common cancer type and the sixth most common cause of cancer deaths worldwide. The 5-year survival rate in the US is 20%, and 10% in Europe3.

The esophageal cancer trial is an open-label, single-arm, prospective phase I study consisting of two parts: (i) dose-escalation to determine the RP2D of NBTXR3 activated by radiation therapy with concurrent chemotherapy, as per standard of care; and (ii) expansion at the RP2D with toxicity monitoring.

The patient population will include adults (age 18 years) with stage II-III adenocarcinoma of the esophagus that are treatment nave and radiographically non-metastatic at screening. Up to 24 subjects will be enrolled. Recruitment is expected to begin in 4Q2020 and the planned enrollment period is 24 months.

Next Steps for Clinical Collaboration with MD Anderson

The clinical collaboration between Nanobiotix and MD Anderson includes plans for additional clinical trials across several indications. Beyond the three (3) trials mentioned above, the other trials, including four (4) combination trials with immune checkpoint inhibitors and NBTXR3 activated by radiation therapy, are in preparation and will launch in due time.

***

About NBTXR3

NBTXR3 is a novel radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy. The physical and universal mode of action (MoA) of NBTXR3 is designed to trigger cellular destruction death and adaptive immune response.

NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers. In February 2020, the United States Food and Drug Administration granted the regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.

Nanobiotix is also running an Immuno-Oncology development program. The Company has launched a Phase I clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets) from any primary cancer eligible for anti-PD-1 therapy.

Other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and pancreatic cancer. The Company is also engaged in a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to further expand the NBTXR3 development program.

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.20-010 on May 12, 2020 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

1https://www.cancer.net/cancer-types/pancreatic-cancer/statistics

2https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics

3https://www.cancer.net/cancer-types/esophageal-cancer/statistics

View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005825/en/

Originally posted here:
NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From US FDA -...

Read the Rest...

Quilts for pancreatic cancer patients and research – University of Strathclyde

§ October 16th, 2020 § Filed under Nano Medicine Comments Off on Quilts for pancreatic cancer patients and research – University of Strathclyde

Chemistry researchers at the University of Strathclyde are aiming to raise awareness of pancreatic cancer with the use of specially-made quilts.

Fellow cancer researchers across the UK are being asked to send diagrams illustrating their work. These will then be used as the patterns for quilts made by skilled crafters.

After the project is concluded, the Strathclyde researchers hope to be able to display the quilts in an exhibition, which may be held online if a physical exhibition is not possible. The quilts will then be donated to local pancreatic cancer patients

The project, titled Quilts4Cancer, is being funded through a grant of 4700 from the Royal Society of Chemistry.

Nearly 9,500 people each year are diagnosed with pancreatic cancer in the UK.

Dr Clare Hoskins, a Reader in Strathclydes Department of Pure and Applied Chemistry, is leading Quilts4Cancer, along with Dr Kirsty Ross, the Departments Outreach Officer. The programme is being launched to coincide with Pancreatic Cancer Awareness Month in November.

Dr Hoskins said: Funds for cancer research have dropped significantly in the pandemic but we aim to raise awareness of chemistry research across the UK towards better therapies for pancreatic cancer, as well as raising awareness of its signs and symptoms.

We chose to have quilts made because its known that chemotherapy patients get cold during their treatment. The therapy has serious side effects but we want to raise awareness of the new technology and compounds coming through; a lot of work is being done on making treatment safer, with fewer side effects.

Were asking for researchers in the chemical sciences to send simple diagrams based on their research, with small summaries of what it is and who is carrying it out. It could show the chemical structures of treatments or technology such as ultrasound equipment.

My design illustrates my research in laser-activated nanomedicine. It shows nanoparticles which have been found to penetrate deep into pancreatic tumour tissue, allowing for drug treatments to reach the site where they are required and help reduce the unpleasant side effects. These nanoparticles act as chaperones for the drug molecules, carrying their cargo past the bodys defence systems and to their target site.

On arrival, a laser beam activates them to release their drugs, making them more effective than conventional chemotherapy. The nanocarriers themselves are relatively simple and cheap to make and they can be easily tailored for different uses and cancer types.

Dr Hoskins and Dr Ross have created a Quilts4Cancer Facebook page. Anyone wishing to participate in the project can contact Dr Hoskins.

The project will hold evening stitching sessions throughout November. Register for the sessions.

Visit link:
Quilts for pancreatic cancer patients and research - University of Strathclyde

Read the Rest...

R&D Activities to Fast-track the Growth of the Healthcare Nanotechnology (Nanomedicine) Market Between 2015 2021 – PRnews Leader

§ October 16th, 2020 § Filed under Nano Medicine Comments Off on R&D Activities to Fast-track the Growth of the Healthcare Nanotechnology (Nanomedicine) Market Between 2015 2021 – PRnews Leader

Given the debilitating impact of COVID-19 (Coronavirus) on the Healthcare Nanotechnology (Nanomedicine) market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Healthcare Nanotechnology (Nanomedicine) market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

The report provides both quantitative and qualitative information of global Healthcare Nanotechnology (Nanomedicine) market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Healthcare Nanotechnology (Nanomedicine) is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Healthcare Nanotechnology (Nanomedicine) market was valued at USD _ million/billion.

This research report based on Healthcare Nanotechnology (Nanomedicine) market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Healthcare Nanotechnology (Nanomedicine) market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Healthcare Nanotechnology (Nanomedicine) industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/6370

Healthcare Nanotechnology (Nanomedicine) Market Overview:

The Research projects that the Healthcare Nanotechnology (Nanomedicine) market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.

Leading manufacturers of Healthcare Nanotechnology (Nanomedicine) Market:

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/6370

Some important highlights from the report include:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/6370

The Questions Answered by Healthcare Nanotechnology (Nanomedicine) Market Report:

And Many More.

Read more from the original source:
R&D Activities to Fast-track the Growth of the Healthcare Nanotechnology (Nanomedicine) Market Between 2015 2021 - PRnews Leader

Read the Rest...

Global Artificial Intelligence Drug R&D Market 2020 Growth Drivers, Investment Opportunity and Product Developments 2025 Wall Street Call – Reported…

§ October 14th, 2020 § Filed under Nano Medicine Comments Off on Global Artificial Intelligence Drug R&D Market 2020 Growth Drivers, Investment Opportunity and Product Developments 2025 Wall Street Call – Reported…

Oct 13, 2020 9:47 AM ET iCrowd Newswire Oct 13, 2020

MarketandResearch.biz has released a new market research report namely, Global Artificial Intelligence Drug R&D Market Growth (Status and Outlook) 2020-2025 that will provide you every microscopic detail about the market. The report comprises an evaluation of distinct parameters that elevate the growth of the global industry. The major topics of global Artificial Intelligence Drug R&D market document are: Overview of industry, development, and manufacturing plants analysis, major manufacturers analysis, development trend analysis, key figures of major manufacturers, market dynamics, segment market analysis by type and by application, and regional market analysis, the market forecast for 2020 to 2025 time-period. The report throws light on aspects such as the growth factors, limitations of the market, future, and current challenges of the market along with the opportunities.

Competitive Landscape:

Various companies are covered to understand the products and/services relevant to the global Artificial Intelligence Drug R&D market. The report includes information such as gross revenue, production and consumption, average product price, and market shares of key players. The vendors are gradually widening their strategic moves to attract customers. Global Artificial Intelligence Drug R&D market competition has been assessed by top manufacturers, with production, price, and revenue (value) and market share for each manufacturer. Additionally, competitive analysis and trends, mergers & acquisitions, and expansion strategies are derived.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketandresearch.biz/sample-request/150020

Market Dynamics:

The global Artificial Intelligence Drug R&D market has been analyzed using various relevant factors that are expected to influence market growth in forthcoming years. Such factors include positive market influencers as well as negative influencers. The positive factors are analyzed for their growth promotion tendencies, as well as the negative factors that are analyzed for reasons why they are restraining the market growth. These dynamics will help the reader understand the growth trajectory taken by the market in the forthcoming years.

Global key players of Artificial Intelligence Drug R&D market included are: IBM Watson, Phenomic AI, BioXel, Gatehouse Bio, Google DeepMind, Insilico Medicine, QuantumBlack, Genpact Cora, Nq Medical, Cyclica Inc, Palantir Technologies,

Market research supported product sort includes: AI Platfrom, Analytics Service,

Market research supported application coverage: Drug Discovery, Precision Medicine,

Moreover, each geographic segment of the global Artificial Intelligence Drug R&D market has been independently surveyed along with pricing, distribution and demand data for geographic market notably: Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

ACCESS FULL REPORT: https://www.marketandresearch.biz/report/150020/global-artificial-intelligence-drug-rd-market-growth-status-and-outlook-2020-2025

The Artificial Intelligence Drug R&D Market With Respect To The Geographical Terrain:

The report deeply examines the market with reference to geographical topography, which is divided into Artificial Intelligence Drug R&D. Details about the sales acquired by each region as well as their market share are discussed in the report. This research highlights key insights that will affect the growth of every region and revenue generated by listed geographies over the projected timeframe.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketandresearch.biz

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at [emailprotected].

Original post:
Global Artificial Intelligence Drug R&D Market 2020 Growth Drivers, Investment Opportunity and Product Developments 2025 Wall Street Call - Reported...

Read the Rest...

Introducing the 2020 AAMC award winners – AAMC

§ October 14th, 2020 § Filed under Nano Medicine Comments Off on Introducing the 2020 AAMC award winners – AAMC

The developers of a pioneering gene therapy to treat blindness. A health policy expert who was instrumental in the drafting of the Affordable Care Act. A medical school whose commitment to the community extends from creating a COVID-19 clinic for homeless residents to partnering with the local school system to champion careers in health care. These are a few of the recipients of the 2020 AAMC Awards, which recognize individuals and institutions that have made outstanding contributions in medical education, biomedical research, clinical care, and community engagement. The awardees will be recognized during a video tribute in November at Learn Serve Lead 2020: The Virtual Experience.

Sondra Zabar, MD: 2020 Abraham Flexner Award for Distinguished Service to Medical Education

Through scholarship, mentorship, and educational and assessment innovation, Sondra Zabar, MD, professor of medicine at NYU Grossman School of Medicine, has been on the leading edge of teaching and evaluating clinical care. She pioneered the use of unannounced standardized patients to assess trainees clinical performance, and she leads the Standardized Patient Program at NYU/New York Simulation Center, which serves more than 15,000 learners every year. She is a diligent and rigorous scholar, having published more than 70 peer-reviewed articles and authored the seminal textbook on objective structured clinical examinations. She also founded the Program in Medical Education Innovations and Research, which has awarded more than 30 teaching fellowships and 50 seed grants to advance medical education scholarship and institute patient-centered best practices. Dr. Zabars accolades include the Distinguished Teaching Award, NYUs most prestigious educational honor, and the Medical Educator Award and the Scholarship in Medical Education Award from the Society of General Internal Medicine.

Jean Bennett, MD, PhD, and Albert M. Maguire, MD: 2020 Award for Distinguished Research in the Biomedical Sciences

Countless people around the world who were blinded by a once-untreatable disease can now see because of a pioneering gene therapy developed by Jean Bennett, MD, PhD, and Albert M. Maguire, MD, professors of ophthalmology at the Perelman School of Medicine (PSOM) at the University of Pennsylvania. By creating the first gene therapy to treat blindness, Drs. Bennett and Maguire not only reversed the effects of an inherited retinal degenerative disease, Leber congenital amaurosis (LCA), but ignited new research to combat other genetic causes of blindness as well. The therapy, approved by the Food and Drug Administration in 2017 and named Luxturna, replaces a mutated gene, RPE65, that triggers LCA. Drs. Bennett and Maguire continue to lead the development of therapies for impaired vision through their own research and by supporting the work and building the careers of other scientists. They also established the Center for Advanced Retinal and Ocular Therapeutics at PSOM to advance treatments for retinal and ocular diseases through research and training.

Ezekiel J. Zeke Emanuel, MD, PhD: 2020 Robert Wood Johnson Foundation David E. Rogers Award

Few physicians have had as demonstrable an effect on improving the health of Americans in the 21st century as Ezekiel J. Emanuel, MD, PhD, vice provost for global initiatives at the Perelman School of Medicine at the University of Pennsylvania. As special advisor on health policy to the Office of Management and Budget from 2009 to 2011, Dr. Emanuel was instrumental in the drafting and early implementation of the Affordable Care Act, the nations most sweeping health reform law in decades. A renowned bioethicist, Dr. Emanuel has also indelibly shaped clinical research ethics. As founding chair of the Department of Bioethics at the National Institutes of Health for 14 years, Dr. Emanuel led the creation of a training program for bioethicists; initiated the revision of the Common Rule, which brought significant reform to regulations in research involving human subjects; and was integral to crafting the latest Declaration of Helsinki, the World Medical Associations policy statement on medical research involving human subjects.

Cato T. Laurencin, MD, PhD: 2020 Herbert W. Nickens Award

Cato T. Laurencin, MD, PhD, has distinguished himself throughout his 40-year career as a phenomenal physician-scientist and a courageous leader in social justice, equity, and fairness. Through his scholarship and national, regional, and community efforts, he has worked to make a difference in the lives of people affected by racial and ethnic health disparities. Dr. Laurencinco-founded the W. Montague Cobb/National Medical Association Health Institute in Washington, DC, which focuses on addressing health disparities, and he is the founding editor-in-chief of the Journal of Racial and Ethnic Health Disparities. An outstanding administrator and practicing orthopedic surgeon, he previously served as dean of the University of Connecticut (UConn) School of Medicine and vice president of health affairs at UConn. Dr. Laurencin is also an extraordinary scientist whose research has yielded more than 500 publications and patents. He is the first person in history to win both the highest award of the National Academy of Medicine, the Walsh McDermott Medal, and the highest award of the National Academy of Engineering, the Simon Ramo Founders Award. President Obama presented the 2016 National Medal of Technology and Innovation Americas highest award for technological achievement to Dr. Laurencin.

Patricia Garcia, MD, MPH: 2020 Arnold P. Gold Foundation Humanism in Medicine Award

Patricia Garcia, MD, MPH, associate dean for curriculum at Northwestern University Feinberg School of Medicine in Chicago, exemplifies humanism in medicine, working tirelessly to champion her patients, students, and a better society. Attending medical school in the 1980s, Dr. Garcia became intensely interested in caring for patients with HIV and AIDS. As a fellow, she co-founded the first womens HIV program at Northwestern Memorial Hospital. Today, the clinic has a 99% success rate in eliminating maternal-fetal transmission of HIV. She founded the Pediatric AIDS Chicago Prevention Initiative and traveled to labor and delivery units throughout Illinois to train staff in how to perform HIV testing for pregnant mothers and ensure transmission-preventing treatment could be provided. Dr. Garcia is also a big supporter of student-led initiatives, including a recent health care hackathon and the creation of Safe Space Training for faculty and staff, an initiative to improve the learning environment for LGBT+ students.

Rush Medical College of Rush University Medical Center: 2020 Spencer Foreman Award for Outstanding Community Engagement

Established in 1837, Rush Medical College of Rush University Medical Center in Chicago is a trusted service provider and anchor institution where learners, faculty, staff, and administrators continually demonstrate their commitment to the community. At the outset of the COVID-19 pandemic, Rush created the Chicago Homelessness and Health Response Group and Equity (CHHRGE) as an extension of one of the 35 ongoing programs of the Rush Community Service Initiatives Program. Faculty stepped in to provide care for people experiencing homelessness and, working closely with the citys public health officials, CHHRGE continues to administer tests, address outbreaks, provide behavioral health services, and identify gaps in care coordination while laying out a plan for permanent housing. This is just the latest example of the institutions commitment to the health and well-being of its neighbors. Rushs focused recruiting practices leverage community partnerships to provide critical support to job applicants during the hiring process and beyond. Rush is also committed to creating a diverse pipeline of health professionals by working with local students. In particular, Rush has been providing mentoring, tutoring, shadowing, and exposure to health careers to students at the reinvented Richard T. Crane Medical Preparatory High School since 2013.

John W. Bigbee, PhD: 2020 Alpha Omega Alpha Robert J. Glaser Distinguished Teacher Award

Over three decades, John W. Bigbee, PhD, a professor in the Department of Anatomy and Neurobiology at Virginia Commonwealth University School of Medicine, has developed a reputation as an innovative and enthusiastic educator. Throughout his career, he has spent countless hours developing innovative materials and original images to use in teaching students about the microscopic anatomy of tissues. Recognizing changes to educational laboratory environments and the power of technology in the 1990s, Dr. Bigbee and colleague Alice Pakurar, PhD, led an ambitious project to create what he describes as an interactive digital atlas of more than 1,200 histology images and illustrations and associated learning materials. First engineered on CD-ROM in 1998, Digital Histology is now available as an open educational resource for histology learners around the globe. Dr. Bigbees dedication to his learners is also evident from the awards they have bestowed on him, including 27 Outstanding Teaching Awards and the 2002 VCU Award for Innovating Excellence in Teaching, Learning and Technology.

Marianne M. Green, MD, FACP: 2020 Alpha Omega Alpha Robert J. Glaser Distinguished Teacher Award

Since joining the faculty at Northwestern University Feinberg School of Medicine in 1997, Marianne M. Green, MD, FACP, has pioneered educational reform. Under Dr. Greens leadership, Feinberg was among the first medical schools to modernize its curriculum and implement a comprehensive electronic portfolio-based assessment system, which permits the longitudinal measurement of competency achievement and individualized student support for learning.

Dr. Green, who is now senior associate dean for medical education, has led the implementation of several additional curricular innovations at Feinberg. They include implementing the schools first clerkship-associated objective structured clinical examination; designing and implementing an electronic tracking system to better review longitudinal student performance; and designing and implementing competency-based medical education. Currently, Dr. Green is leading a team to implement an entrustable professional activities framework into the competency-based assessment system. She has received more than a dozen teaching awards, including the schools most selective, the George H. Joost Award for Teaching.

Paul A. Hemmer, MD, MPH, MACP: 2020 Alpha Omega Alpha Robert J. Glaser Distinguished Teacher Award

Ever passionate about student and faculty development, Paul A. Hemmer, MD, MPH, MACP, has dedicated his career to improving medical education. As vice chair for educational programs at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland, Dr. Hemmer oversees all pre-clerkship educational programs and intradepartmental courses, all medicine clerkship sites in the continental United States and Hawaii, M4 electives throughout the United States, and key faculty development programs and initiatives. Dr. Hemmers associated scholarship in evaluation, curriculum, and faculty development and educational research has also earned him national and international praise. He has received numerous honors, including Academic Grand Master of the U.S. Air Force; the Patil Award for Assessment by the Association for Medical Education in Europe; the Ruth-Marie E. Fincher, MD, Service Award from the Clerkship Directors in Internal Medicine; the Lifetime Achievement Award from the University of Wisconsin-Milwaukee Alumni Association; the Laureate Award from the Air Force Chapter of the American College of Physicians; and the Carol Johns Medal, the highest honor faculty can bestow at the USUHS.

Daniel R. Wolpaw, MD: 2020 Alpha Omega Alpha Robert J. Glaser Distinguished Teacher Award

Over the past four decades, Daniel R. Wolpaw, MD, has been a force for innovation in medical education, envisioning learner development as a complex adaptive challenge aimed at preparing medical students to lead and practice in the health care systems of the future. As professor of medicine and humanities at Penn State College of Medicine in Hershey, Pennsylvania, Dr. Wolpaws notable contributions include developing and co-directing the Systems Navigation Curriculum, developing and co-directing an innovative course in critical thinking, and serving as the design lead for educational innovation at the schools University Park Regional Campus. Before joining Penn State in 2013, Dr. Wolpaw served on the faculty at Case Western Reserve University School of Medicine for 30 years. At both institutions and nationally, he has received high praise for his extraordinary skills as an educator and mentor. His accolades include the Career Achievements in Medical Education Award from the Society of General Internal Medicine and the Newark Beth Israel Healthcare Foundation Humanism in Medicine Award.

For more information about the 2020 awardees, read more here.

Nominations for the 2021 AAMC Awards are now open. Visitaamc.org/awardsto learn more about the criteria and submit a nomination.

Read the rest here:
Introducing the 2020 AAMC award winners - AAMC

Read the Rest...

Nobel Prize for Medicine awarded to 3 scientist that discovered Hepatitis C virus – RFI English

§ October 14th, 2020 § Filed under Nano Medicine Comments Off on Nobel Prize for Medicine awarded to 3 scientist that discovered Hepatitis C virus – RFI English

Issued on: 08/10/2020 - 09:47

The 2020 Nobel Prize in medicine was awarded to Harvey Alter, Michael Houghton and Charles Rice for the discovery of the Hepatitis C virus (HCV). The discovery of HCV was formally announced in 1989 in a paper published by Dr Alter and Dr Houghton.

It took a further 27 years before thestructure of the virus was observed for the firsttime and in doing so took the Noble prize winners' discovery forward.

In fact, in what was alsoa world first, French scientists from Inserm and University of Tours observed its structure under an electron microscope in 2016.

Its an exceptional virus and a remarkable discovery. Normally, observation plays a key role in virus discovery. However, in this case, for 25 years after its discovery the structure of the virus could be deduced only through molecular biology, Dr Phillipe Roingeard, professor of medicine at the University of Tours, told RFI.

The reason why the HCV, which belongs to the flavivirus community, remained so elusive was because of its unique ability to mask itself as lipid particles such as cholesterol. Moreover, it is present in much smaller amounts compared to the Hepatitis B virus. And unlike other viruses, it cannot be grown in cells in a laboratory.

As a result, the virus remains hidden to the immune system of an infected person, Dr Roingeard said.

The French researchers started working on a new technique from 2011 to observe the virus under an electron microscope.

Unlike a conventional microscope which uses light, an electron microscope uses a beam of electrons to observe a microscopic object.

An electron microscope is thousands of times more powerful than a typical lab microscope.

Researchers from all over the world had tried observing the viral structure under electron microscopes but to no avail.

The virus is fragile. It would get damaged during the standard techniques of sample purification and centrifugation processes. It wasnt possible to observe the virus without manipulating it, Dr Roingeard explained.

However, the French team managed to overcome these obstacles. Their technique consisted of trapping the virus with antibodies on the electron microscope grids. It took several attempts during the five years before they managed to obtain the first direct image of the structure of the virus in 2016.

The structure observed by Dr Roingeard and his team corresponds perfectly to the one predicted by scientists based on molecular biology. The virus has a strange structure, similar to that of a lipid. This is something you dont see in any other viruses, he added.

Continue reading here:
Nobel Prize for Medicine awarded to 3 scientist that discovered Hepatitis C virus - RFI English

Read the Rest...

ACSH in the Media: September 2020 – American Council on Science and Health

§ October 14th, 2020 § Filed under Nano Medicine Comments Off on ACSH in the Media: September 2020 – American Council on Science and Health

Actually, a Chinese Virologist Didnt Prove that COVID-19 Was Man-Made -- When journalists the world over a few weeks back were diving deeper into the unsupported claim that the coronavirus might be a human creation tied to nefarioususes, a little-known outfit called TheNew York Timeshappened to call upon ACSH.

In trying to provide clarification regarding this controversial subject,Kevin Roose, acontributing reporter to the newspaper's Daily Distortions column, chose to cite one of our scientific experts, writing: The most straightforward explanation for the suspicious genetic traitsis natural recombination with other coronaviruses,Alex Berezow, a microbiologist, wrote in an article for the American Council on Science and Health." And not only did thatSept. 18 report receive widespread attention in and around the Northeast, it also led to widespread re-publication placements in six other major U.S. newspapers, including the Chicago Tribune, Baltimore Sun, the Orlando Sentinel, the Hartford Courant, the South Florida Sun Sentinel and the Virginian-Pilotof Norfolk, VA.

Scientific Journals Are Now Like Facebook-- An article by Dr. Chuck Dinerstein, our Director of Medicine, was featured on Real Clear Science. Under a large photo of CEO Mark Zuckerberg, our good doctor begins: "Bad behavior has consequences, except when you are a social media platform. But the number of peer-reviewed articles subsequently retracted raises the question of whether medical journals believe that they too are 'platforms,'without responsibility for what they publish and disseminate."

ArangoOpposition to Marijuana Legalization is Misguided -- In a recent opinion column about a New Jersey politician published on NJ.com, Dr. Berezow was quoted, statingthat legalization took away some of the mystique associated with marijuana. Teenagers can be rebellious and are often attracted to things they know they shouldnt do. But smoking a joint is hardly taboo anymore.

Public Mistrust of Science? Challenges & Opportunities-- Under this headline in the well-read website Medium.com, ACSH was featured mid-month with this prominent pull-quote in a thought-provokingarticle on the issue of credibility in science writing.

The Risk of Airline Travel Increases Due to Coronavirus -- On Sept. 10, Dr. Berezowwas quoted about cabin air quality,which he reports is surprisingly good. But instead, he added, travelers should focus on other areas of concern.

Airplane air is fresh and probably cleaner than office air. The airplanes cabin air is completely refreshed 20 times an hour. They also use HEPA filters, which should remove most viral particles, Dr. Berezow stated. But the "biggest concerns" he added, are "bathrooms and tabletops and being in close quarters with other people. He singled out commodes as the greatest danger, explaining, The bathroom is a festering petri plate.One solution is to carry disinfectant wipes with you and wipe stuff down. Thats what I do.

WHY HAVE YOU ABANDONED PAIN PATIENTS WHILE U.S. DOCTORS SUPPORT THEM?-- Dr. Josh Bloom, our Director of Chemical and Pharmaceutical Science and a recognized expert in the realm of medicated pain management, was quoted in this open letter by theChronic Pain Association of Canadato the Canadian Medical Association (Canada's equivalent of the AMA in the U.S.).

Experts Warn of Chinas Emergency Use of COVID-19 Vaccine -- ACSH was referenced in an article posted on the website of Voice of America, on the relative effectiveness of vaccines.

Kirby Wilbur Radio Show On Sept. 15 and 29, Dr. Berezow appeared on the Seattle-based talk show Kirby Nation on KVI, discussing the efforts and obstacles in the search for a COVID-19 vaccine.

And speaking of obstacles ...

Make sure you absolutely steer clear from that random moose when you're driving down the highway. Yes, working to assess relative risk for visitors to the mountainous, Northeastern region while on the road, the Adirondack Almanack (cute spelling, right?)checked in withus before posting its article titledAdirondack Moose Sightings: Rare and Majestic.

Cautioning vacationers to be aware, the AA wrote, citing some of our previous work,that: "Studies done by the American Council on Science and Health show the center of mass of a moose is above the hood of most passenger cars. In a collision, impact studies show that it crushes the front roof beams and individuals in the front seats. Collisions of this type often end in a fatality, leaving seat belts and airbags irrelevant in providing safety."

So not only can media outlets (and mountain men) across the county count on us to assess safety threats like microscopic COVID-19, they also have a go-to source on the dangers of unexpected meet-ups with majestic creatures weighing 1,000 pounds ormore.

Continued here:
ACSH in the Media: September 2020 - American Council on Science and Health

Read the Rest...

Antibiotic Treatment for UTI – What Antibiotics Are Used for UTIs? – Prevention.com

§ October 14th, 2020 § Filed under Nano Medicine Comments Off on Antibiotic Treatment for UTI – What Antibiotics Are Used for UTIs? – Prevention.com

There is nothing fun about getting a urinary tract infection (UTI). It makes it burn when you pee, you feel like you need to run to the john all of the time, and when you do, your urine smells kind of funky. UTIs are downright painful and frustrating, and for that you can thank the bacteria wreaking havoc in your bodys drainage system.

Thankfully, doctors know that antibiotics are some of the best treatments to wipe out those menacing germsand fast! But figuring out the right prescription to beat your specific infection may be a bit of a process. And knowing how to properly take your meds could save you from future infection and other complications.

In order to help you understand what you need to know about antibiotics and UTIs, weve tapped on the pros: experts from MCG Health, a company that compiles evidence-based guidelines so that patients and physicians can work together to create individualized care plans.

So, before you head to your next doctors appointment, read on: Youll know exactly what to ask and what to expect, so you can say goodbye to that bothersome UTI.

Most of the time when you go #1, what flows out flushes away some of the troublesome microbes hanging out around your nether region.

Usually urine is sterile so theres no bacteria in it, explains Sabitha Rajan, M.D., MSc, associate managing editor at MCG. One of the things that keeps us sterile is its continuous flow. Urine flows out of your bladder, down and out your urethra [the emptying tube], and that flow keeps any bacteria from the outside from ascending.

Proper hygiene helps keep bacteria at bay (thats why when you were a kid, your parents may have told you to wipe front to back)but even the cleanest among us can get a UTI. Keep an eye out for these common symptoms:

Women tend to be more susceptible to UTIs, partly because of the way their bodies are built, says Cheyenne Santiago, R.N., M.S.N., a managing editor at MCG. Men have a longer urethra that runs through the penis and farther away from the anus, so there is less of a chance for bacteria from stool and other sources to make their way to where they can cause problems.

Women, on the other hand, have a very short urethra, says Santiago. So [women] can get bacteria forced up into your bladder.

Sex can also increase the risk of UTIs in women and so Santiago and Dr. Rajan recommend going to the bathroom after intercourse.

Whichever the cause of your UTI, you should always schedule a visit with your primary care physician so they can get you the proper treatment.

Once you get to the doctors office, they are going to ask you about your symptoms and make you pee in a cup. This is called a urinalysis (analysis of your urine).

Theyll look at it under a microscope and also dip it, says Dr. Rajan. The dipstick will tell the doctor very quickly if theres any white blood cells, which is a sign of infection, or red blood cells, which could be a sign of some microscopic trauma.

They will then send some of your pee off to a lab where they can test to see which bacteria is causing your infection. The results usually come back to you within one to two days. However, depending on how strongly your doctor feels that you have a UTI, they may put you on antibiotics right away. When the test arrives, they will double-check to see if they have selected the most effective meds to fight off the bacteria and make any needed adjustments.

There are three factors your doctor considers when they are deciding on an antibiotic, according to Dr. Rajan.

First, they need to make sure the medication they select will target the area thats affected. For a UTI, your bladder is the organ that needs the TLC. Second, your docs will check for what they call the local resistance pattern in your town or city.

Theres always a little bit of variation in the kinds of bacteria in a region, explains Santiago. That bacteria becomes more resistant to certain medications and those patterns are different from area to area. So, you may know that in the local area, a lot of women are coming in with a urinary tract infection and maybe a certain drug isnt really working for them, and they really need another one instead because of the strain that were seeing.

Your care team will also consider your medical history, like whether youre allergic to penicillin, or if you are predisposed to certain bacterial infections. If cost is a concern, your physician may even be able to find a treatment that fits your budget or is supported by your insurance, says Santiago.

The most commonly used antibiotics for UTIs include:

Make sure to ask your doctor which one they have prescribed you, so that you know what you are taking.

After a few days of taking the right antibiotics, youre going to be feeling pretty good. Going to the bathroom will be a breeze. The inflammation will go down. But this might just mean youve only weakened the bacterianot that youve completely zapped them out, says Santiago. Its in this phase that the bacteria can come back with a vengeance and potentially become resistant to the meds that were your savior. So yes, finish the prescribed course even when you feel better.

There was a time when doctors often recommended that women on birth control have a backup barrier method, such as a condom, whenever they had to take antibiotics. But Santiago says that the science on this isnt very clear. Recent research has discovered a correlation between antibiotic use and unintended pregnancies while other studies have not found that connection.

So, this is really something that women need to discuss with their physicians about whether or not there is a potential for lowering the effectiveness of their birth control and whether or not they need to add that barrier contraceptive, suggests Santiago.

Heres the thing about antibiotics: They kill the good bacteria along with the bad. This means as the meds make their way down to the bladder, they can harm some of the microbiome, which is important for your digestion, regulating your immune system, and other functions researchers are beginning to unpack.

The Best Probiotic Supplements for Gut Health

8 Probiotic Foods for Better Digestion

Because of that, doctors will sometimes recommend patients with recurring UTIs take probiotics along with their antibiotics. The theory is that this will re-seed the gut or at least prevent the medicine from killing off too much of the good stuff, says Santiago. However, according to Dr. Rajan, there isnt enough scientific research to say if this approach is effective.

When youve finished the antibiotic, you can try to increase your intake of fermented foods and yogurts, says Dr. Rajan. Theres some evidence that those foods can provide those good bacteria. But I say that with the caveat that we are still learning more about this.

While many people do not have any severe negative reactions to antibiotics, these medications have potential side effects. If you have ...

... while youre taking your medication, see your doctor as soon as possible. If you have a severe allergic reaction, head straight to urgent care.

There are no known effective alternative treatments, but cranberry juice and cranberry juice extract pills may be able to help stop infections from occurring in the first place. Cranberry has a naturally occurring compound that can help prevent some bacteria from sticking to your urethra, says Dr. Rajan.

But its a very small effect, if any, she adds. Just drinking enough fluids can be enough to keep everything flowing and minimize harmful bacteria. But if you enjoy drinking cranberry juice and it doesnt give you a tummy ache, theres no harm in trying it to prevent UTIsnot to treat. If youre on blood-thinners, however, experts say, stay away.

Antibiotics can be really powerful when it comes to treating urinary tract infectionsespecially when they are caught early. Untreated UTIs can lead to kidney infections and other serious complications. So, when you feel like you have one, go see your primary care doctor as soon as you can, and talk about which treatment would be best for you.

Support from readers like you helps us do our best work. Go here to subscribe to Prevention and get 12 FREE gifts. And sign up for our FREE newsletter here for daily health, nutrition, and fitness advice.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Excerpt from:
Antibiotic Treatment for UTI - What Antibiotics Are Used for UTIs? - Prevention.com

Read the Rest...

We all need to act now to prevent COVID-19 spread – The Garden Island

§ October 14th, 2020 § Filed under Nano Medicine Comments Off on We all need to act now to prevent COVID-19 spread – The Garden Island

Please help. We all need to act now. Science and medicine have confirmed that travel spreads the virus. In our state, we have seen this for ourselves. Even with just inter-island quarantine requirements lifted, COVID-19 increased throughout the state.

On Oct. 15, the state plans to reopen trans-Pacific and inter-island travel. The problem, only some passengers will have a pre-flight negative COVID-19 test within 72 hours of travel. How can that be safe for Hawaii? For those who test, the current plan is no quarantine required. Not only can those passengers be exposed between their test and their flight, but they will be flying for five hours or more in a confined space with passengers who opt not to test but choose to quarantine after their arrival.

After you read the following, send an email to each of the addressees below. Please insist that our state officials revise this shortsighted and clearly-flawed plan. Share and circulate this email with friends and family. The state needs to hear from as many as possible.

If the plan is revised to require those who pretest to enter a shortened quarantine, with a second test seven days after they were last tested, to assure they havent picked it up, releasing into the economy at that point would keep Hawaii and its residents much safer. It is up to us, everyone needs to say something now. The pressure to restore the economy is real and significant. We do need to take steps to help our economy but lets at least do it responsibly. Recently, the states current flawed plan was featured on the news. I was called by a news reporter and asked for comment: https://www.hawaiinewsnow.com/2020/09/30/councilman-calls-governor-prove-hawaii-is-ready-welcome-back-visitors/

Because some may opt out of the testing and choose to quarantine, theres concern about flights arriving with a mixture of tested and untested passengers.

The airlines, I think, would sell a lot more seats if they could tell people you could ride on this plane and everybody on the plane is negative for COVID including the crew, and how many more seats would they sell and how much better would that be for the state, said Bridget Hammerquist of Kauai.

Lt. Gov. Josh Green says the chances of contracting COVID-19 on any flight are very low, especially if everyone wears a mask.

It should be very safe. Its not ever going to be 100% with the virus in society, but we will have the safest flights in the world because we will have this extra layer of security, and thats a good thing, said Green. Earlier this month, Green said just the opposite:

He said he strongly believes he was exposed during a car ride, because masks cant be perfect.

I wore a mask in the car, on the plane, when I was walking to the ER, and in the ER, everywhere. But we were in the car for over an hour, sipping coffee and breathing the same air inside of a car just a couple of feet away from each other, he said of his colleague. https://www.civilbeat.org/2020/09/lt-gov-josh-green-i-dont-feel-differently-at-all/

And the plane flight will be different? If our lieutenant governor can contract COVID-19 while wearing a mask, riding in a car, some of the pre-flight-tested passengers will just as likely pick up COVID-19 from any of the untested passengers they fly with during that five or more hours in the air. Please email each of the following and beg them to do everything they can to change the current plan to reopen the state. Use any of this email or your own words, but individual messages are needed now:

Governor David Y. Ige: Governor.Ige@hawaii.gov;

Green: josh.green@hawaii.gov;

Mayor Derek Kawakami: dkawakami@kauai.gov;

Maui Mayor Mike Victorino: Mayors.Office@co.maui.hi.us;

Hawaii Mayor Harry Kim: Harry.Kim@hawaiicounty.gov;

Honolulu Mayor Kirk Caldwell: Mayor@honolulu.gov.

If youd like to hear our lieutenant governor with an even stronger statement on why reopening is certain to bring more cases of COVID-19, see and hear him on Mel Rapozos YouTube video, Rapozos COVID-19 Discussion with Lt. Gov. Josh Green, August 12, 2020 https://www.youtube.com/watch?v=tVnwoqPUM-0&t=2190s

Bridget Hammerquist is a resident of Koloa.

Continued here:
We all need to act now to prevent COVID-19 spread - The Garden Island

Read the Rest...

Global 2-Chloro-5-chloromethylpyridine (CCMP) Market 2020 Industry Outlook, Comprehensive Insights, Growth and Forecast 2025 Wall Street Call -…

§ October 14th, 2020 § Filed under Nano Medicine Comments Off on Global 2-Chloro-5-chloromethylpyridine (CCMP) Market 2020 Industry Outlook, Comprehensive Insights, Growth and Forecast 2025 Wall Street Call -…

Oct 13, 2020 8:07 AM ET iCrowd Newswire Oct 13, 2020

MarketandResearch.biz has released a new market research report namely, Global 2-Chloro-5-chloromethylpyridine (CCMP) Market Growth 2020-2025 that will provide you every microscopic detail about the market. The report comprises an evaluation of distinct parameters that elevate the growth of the global industry. The major topics of global 2-Chloro-5-chloromethylpyridine (CCMP) market document are: Overview of industry, development, and manufacturing plants analysis, major manufacturers analysis, development trend analysis, key figures of major manufacturers, market dynamics, segment market analysis by type and by application, and regional market analysis, the market forecast for 2020 to 2025 time-period. The report throws light on aspects such as the growth factors, limitations of the market, future, and current challenges of the market along with the opportunities.

Competitive Landscape:

Various companies are covered to understand the products and/services relevant to the global 2-Chloro-5-chloromethylpyridine (CCMP) market. The report includes information such as gross revenue, production and consumption, average product price, and market shares of key players. The vendors are gradually widening their strategic moves to attract customers. Global 2-Chloro-5-chloromethylpyridine (CCMP) market competition has been assessed by top manufacturers, with production, price, and revenue (value) and market share for each manufacturer. Additionally, competitive analysis and trends, mergers & acquisitions, and expansion strategies are derived.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketandresearch.biz/sample-request/150042

Market Dynamics:

The global 2-Chloro-5-chloromethylpyridine (CCMP) market has been analyzed using various relevant factors that are expected to influence market growth in forthcoming years. Such factors include positive market influencers as well as negative influencers. The positive factors are analyzed for their growth promotion tendencies, as well as the negative factors that are analyzed for reasons why they are restraining the market growth. These dynamics will help the reader understand the growth trajectory taken by the market in the forthcoming years.

Global key players of 2-Chloro-5-chloromethylpyridine (CCMP) market included are: Hailir Pesticides and Chemicals Group, Nantong Cusuan Huagong, Jiangsu Yangnong Chemical Group, Puyang Yuandong Huagong, Shandong Sino-Agri Union, Jiangsu Changqing Agrochemical, Tendenci Chem, Jiagnsu Subin Agrochemical, Zhejiang Avilive, Shandong Huimeng Biotech, Jiangsu Jiannong ABA Agrochemical,

Market research supported product sort includes: Above 98%, 90%-98%, Less than 90%,

Market research supported application coverage: Agriculture, Medicine,

Moreover, each geographic segment of the global 2-Chloro-5-chloromethylpyridine (CCMP) market has been independently surveyed along with pricing, distribution and demand data for geographic market notably: Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

ACCESS FULL REPORT: https://www.marketandresearch.biz/report/150042/global-2-chloro-5-chloromethylpyridine-ccmp-market-growth-2020-2025

The 2-Chloro-5-chloromethylpyridine (CCMP) Market With Respect To The Geographical Terrain:

The report deeply examines the market with reference to geographical topography, which is divided into 2-Chloro-5-chloromethylpyridine (CCMP). Details about the sales acquired by each region as well as their market share are discussed in the report. This research highlights key insights that will affect the growth of every region and revenue generated by listed geographies over the projected timeframe.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact Us

Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: [emailprotected] Web: http://www.marketandresearch.biz

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at [emailprotected].

Read this article:
Global 2-Chloro-5-chloromethylpyridine (CCMP) Market 2020 Industry Outlook, Comprehensive Insights, Growth and Forecast 2025 Wall Street Call -...

Read the Rest...

How many organs are in the human body? – Live Science

§ October 11th, 2020 § Filed under Nano Medicine Comments Off on How many organs are in the human body? – Live Science

Since ancient times, humankind has sought to understand the guts inside us. Ancient Egyptians handled human organs as they removed them for embalming. Medical manuscripts found in an ancient Chinese tomb may be the earliest-known anatomical writing about the human body. Thousands of years later, do we know how many organs are in the human body?

Organs are collections of tissues that work together for a common goal, explained Lisa M.J. Lee, an associate professor in the Department of Cell & Developmental Biology at the University of Colorado School of Medicine. "Every organ provides a function for human performance or survival," she told Live Science.

But not every organ is necessary for survival. Only five organs the brain, heart, liver, at least one kidney, and at least one lung are absolutely essential for living. Losing total function of any one of these vital organs spells death. Remarkably, the human body can survive without a lot of other organs, or by replacing a non-functioning organ with a medical device.

Related: Why do we have an appendix?

As for counting organs in the human body, it depends on whom you ask and how you count, Lee said. Although no one knows where the number originates, the general count is 78 organs, she said. This list includes the vital organs: the tongue, stomach, thyroid, urethra, pancreas, plus many other single or pairs of organs. Bones and teeth are each counted only once.

Among anatomists, viewpoints differ on what counts as an organ. A histologist like Lee, who studies tissue at the microscopic level, may have a longer list of organs than a gross anatomist, who studies what's visible to the unaided eye. For example, scientists made headlines in 2017 for labeling the mesentery, which attaches the intestines to the abdominal wall, as an organ. Even though the scientists provided new evidence to call it an organ, it was not controversial, as many histologists and anatomists agreed, Lee explained. But there's no group charged with keeping an official count of the organs or deciding what qualifies as an organ.

Thinking microscopically, when multiple types of tissues join together and function together, the unit is an organ, she said. Lee could call a nail, or structures that support the nail, an organ, and count each tooth as an individual organ. "I would consider each bone an organ, and all 206 bones collectively together, is considered an organ system." Because bones are already listed once on the list of 78, to get a tally of the total number of organs using this definition, just add 205, for a total of 284 organs.

Counting each tooth separately brings the list to 315 organs. Many other organs are listed only once, even though there are many of them throughout the body. For instance, ligaments and tendons could dramatically increase the total number of organs when counted individually. This game is endless. The list of 78 counts the nerves just once, but there are trillions of them.

Exhausted? Lee often tells her medical and graduate school students to be OK with this type of ambiguity. However you count them, you should take care of the organs you do have, she added. "More and more, I'm finding out how important it is that you put the right stuff in your body to feed your cells, your tissues and your organs," Lee said. After all, the body only has so many performers at its organ recital.

Originally published on Live Science.

View original post here:
How many organs are in the human body? - Live Science

Read the Rest...

« Older Entries



Page 11234..1020..»